Lupin receives tentative approval from USFDA for Oxcarbazepine ER Tablets
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with Spinal Muscular Atrophy (SMA)
33rd lab in Thyrocare’s expanding network to bring advanced, affordable diagnostic services across the Kashmir Valley
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Subscribe To Our Newsletter & Stay Updated